Guest Editor(s)
-
- Dr. Robert Shenkar
Department of Neurosurgery, University of Chicago Medicine and Biological Sciences, Chicago, IL, USA.
Website | E-mail
-
- Dr. Jun Zhang
- Jun Zhang, Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Website | E-mail
Special Issue Introduction
Cerebral cavernous malformations (CCMs) are ectatic capillary-venous malformations that develop in approximately 0.5% of the population. These malformations, which can vary in size from 2 millimeters to several centimeters in diameter, may be hereditary but most often occur on their own as sporadic cases. As opposed to other kinds of hemangiomas, CCM vessels, which have the appearance of a small mulberry, develop and create problems in the brain or spinal cord. Patients with CCMs may develop headaches, focal neurologic deficits, seizures, and hemorrhages. Up to date, neurosurgical resection is the only therapeutic option. Exploring new possible signaling pathways involved in pathogenesis might provide new strategic options for future CCM therapy and management. In this special issue, we aim to report the latest advances of CCMs, specifically in CCM-related signaling pathways and their correspondent therapeutic strategies.
Keywords
Cerebral cavernous malformations, signaling, biomarkers, inflammation, therapeutics
Submission Deadline
31 Aug 2022
Vessel Plus
